Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA Partner Orgs Say Agency Should Repurpose Drugs Through AI, More Biomarker Qualifications

14 August 2026 · By · Wire by Fusion42

Published

14 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at insidehealthpolicy.com →

◆ Verified

Fusion42 · 22 August 2026 · Fusion42 review

Two nonprofit organizations recommend that the FDA advance drug repurposing efforts by expanding biomarker qualifications and standardizing AI use for analyzing evidence.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You can now expect faster pathways for previously approved drugs being repurposed using AI and biomarkers in the US, opening a route to innovate on drug indications without starting trials from scratch.

◆ Coverage

1 source · 14 Aug 2026

◆ Related on Wire

◆ Topics

Biotechfdadrug-repurposingartificial-intelligencebiomarkersregulatory